NCT02632409: A reported trial by Bristol-Myers Squibb
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02632409 |
|---|---|
| Title | A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 22, 2016 |
| Completion date | July 17, 2020 |
| Required reporting date | July 17, 2021, midnight |
| Actual reporting date | July 16, 2021 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |